Clinical trials: Dementia, Alzheimer Type
Dementia, Dementia Alzheimer Type
Dynamic Light Scattering Ocular Measurement in the Detection of Dementia
This is a human clinical study making a noninvasive measurement from a patient's eye to determine whether there is a quantitative difference in measurements between patients with and without the diagnosis of dementia.
- Trial name
- DLS (NCT06613971)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- MD Stem Cells
Amyloid, Medullary Thyroid Cancer
Amyloid Proteins From Medullary Thyroid Cancer and Laryngeal Amyloidosis
Using excess tumour samples that contain amyoid, from patients with Medullary Thyroid Cancer, we aim to determine the structures of ex vivo amyloid fibrils from human tumour tissue samples and compare them with that of existing…
- Conditions
- Amyloid, Medullary Thyroid Cancer, Alzheimer Disease, Dementia
- Trial name
- NCT04760171
- Volunteers
- 10 people
- Sponsor
- The Leeds Teaching Hospitals NHS Trust
Dementia of Alzheimer Type, Dementia Frontotemporal
Multifactorial Approach to Dementia, Multicentric Study
The goal of this observational study is to assess the role of narcisistic personality disorder and life stressful events in conversion rate to dementia, using a three tier approach along three research lines employing subjects…
- Conditions
- Dementia of Alzheimer Type, Dementia Frontotemporal, Narcissistic Personality Disorder, Depression
- Trial name
- NCT05923307
- Where
- Argentina
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Daniel Serrani Azcurra
Alzheimer Disease, Early Onset, Alzheimer Disease
Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks
This study attempts to identify two types of AD by using clinical and cognitive tasks and brain imaging. The subtypes of AD are separated into a "typical" group (memory loss) and a "variant" group (language, visuospatial, and…
- Conditions
- Alzheimer Disease, Early Onset, Alzheimer Disease, Alzheimer Disease, Late Onset, Dementia, Alzheimer Type
- Trial name
- EOAD-Subtype (NCT03153371)
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Mild Cognitive Impairment, Dementia; Alzheimer's Type (Etiology)
STIM+: PET Biomarker Education & Disclosure
When dementia is caused by AD, we refer to it as dementia of the Alzheimer's Type (DAT). The greatest risk factor for Alzheimer's Disease (AD) and DAT is advancing age, but DAT is not a normal part of aging.
- Trial name
- STIM+ (NCT04818255)
- Testing
- PET Biomarker Disclosure
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- University of Michigan
Alzheimer Disease
Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type
Safety and tolerability. Quality of life (EQ-5D, ACQLI) and health economic impact (health resource utilisation, living and employment status) assessments, will not be performed at the centers in the united kingdom (UK)
- Trial name
- NCT02248116
- Testing
- Talsaclidine
- Volunteers
- 198 people
- Sponsor
- Boehringer Ingelheim
Dementia, Alzheimer Type
A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)
This XanADu Phase II study in mild Alzheimer's Disease (AD) is to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's Disease.
- Trial name
- XanADu (NCT02727699)
- Testing
- Xanamem™
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 185 people
- Sponsor
- Actinogen Medical
Diabetes, Chronic Kidney Diseases
Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY)
This research programme seeks to combine the resources of NHS primary care, with the leading spectroscopic work in low-magnetic fields of the Wilson Group (Nottingham Trent University) to demonstrate the potential for benchtop…
- Conditions
- Diabetes, Chronic Kidney Diseases, Cancer, Bowel Disease
- Trial name
- BRANCH-P (NCT05473325)
- Where
- United Kingdom
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Willows Health
Alzheimer Disease
Pre-Clinical (Alzheimers) Diagnosis PCD = Optimum Outcomes OO
This Observational protocol will attempt to verify two recent and very critical concepts in ALZ Clinical Research by studying high-risk individuals who already are taking medications which may prevent the onset of ALZ.
- Trial name
- PCD=OOALZ (NCT02835716)
- Testing
- roflumilast, ustekinumab
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Millennium Magnetic Technologies, LLC
Alzheimer Disease
Sensory Support Care for Elderly Patients Suffering From Alzheimer'S-type Neurodegenerative Disease
The main objective of this study is to evaluate the effect of 3 months of "Snoezelen-type" multi-sensory care sessions on NeuroPsychiatric Inventory Questionnaire (NPI-Q) scores for patients with Alzheimer's-type…
- Trial name
- SensiCare (NCT01819714)
- Testing
- Multi-sensory supportive care
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Dementia, Mild, Dementia of Alzheimer Type
Adaptation of the Uniform Data Set for Telematic Administration
The present project is an evolution of the previous RIN 2019 study aimed at validating and standardizing the Uniform Data Set (UDS) for dementia, a battery of tests exploring various cognitive domains (memory, language, praxis…
- Trial name
- NCT05785910
- Testing
- IUDS
- Where
- Italy
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Alzheimer's Type Dementia
Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease
The purpose of this study is to compare 23 mg donepezil sustained release to the currently marketed formulation of 10 mg donepezil immediate release in patients with severe Alzheimer's disease.
- Trial name
- NCT01539031
- Testing
- E2020
- Where
- 54 sites in Japan
- Volunteers
- 351 people
- Sponsor
- Eisai Co., Ltd.
Severe Alzheimer's Disease
Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease
A 12-week, multicenter, randomized, double-blind, placebo-controlled phase IV study. Approximately 200 subjects will be enrolled, half will receive active drug (donepezil hydrochloride) and half will receive matching placebo at…
- Trial name
- NCT00711204
- Testing
- Donepezil Hydrochloride (Aricept)
- Where
- United States
- Sponsor
- Eisai Inc.
Alzheimer's Disease, Dementia
Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease
Donepezil hydrochloride (Aricept) has been approved to treat symptoms associated with mild to moderate Alzheimer's disease (AD).
- Trial name
- NCT00096473
- Testing
- Donepezil hydrochloride
- Where
- 42 sites in United States, Australia and 4 more
- Volunteers
- 229 people
- Sponsor
- Eisai Inc.
Alzheimer's Disease, Obesity
Intermittent Calorie Restriction, Insulin Resistance, and Biomarkers of Brain Function
Background: Insulin removes sugar from the blood to use for energy. Insulin resistance means that cells may not respond to insulin normally. It can lead to serious diseases.
- Conditions
- Alzheimer's Disease, Obesity, Diabetes Mellitus
- Trial name
- NCT02460783
- Testing
- Boost (R) 5-2 diet, Healthy Living Diet
- Where
- United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Alzheimer Disease
A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients
A 10-week safety and tolerability study of a potential treatment for mild to moderate Alzheimer's disease.
- Trial name
- NCT00141661
- Testing
- PF-04494700 - Low Dose Arm, PF-04494700 - High Dose Arm
- Where
- 12 sites in United States
- Volunteers
- 67 people
- Sponsor
- Pfizer
PARKINSON DISEASE (Disorder), Alzheimer s Disease
Precision Medicine and Neurodegenerative Diseases: Advanced Systems for the Diagnosis and Treatment of Parkinson's Disease and Alzheimer's Disease.
In recent decades, advances in medicine have significantly improved both quality of life and life expectancy. However, these positive effects are also associated with a considerable increase in the prevalence of age-related…
- Conditions
- PARKINSON DISEASE (Disorder), Alzheimer s Disease, Diabete Type 2
- Trial name
- NEUROTECHNO (NCT07467460)
- Where
- Italy
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Neuromed IRCCS
Lung Cancer, Breast Cancer
Telemedicine-mHealth Symptom Cluster Intervention for Advanced Cancer Patients: Finding Our Center Under Stress (FOCUS)
This clinical trial studies whether a telemedicine-mobile health (mHealth) intervention, Finding Our Center Under Stress (FOCUS), improves symptom management in patients with cancer that may have spread from where it first…
- Conditions
- Lung Cancer, Breast Cancer, Prostate Cancer, Multiple Myeloma
- Trial name
- FOCUS (NCT07102212)
- Testing
- mHealth Intervention
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Alzheimer Disease, Diabetes Mellitus, Type 2
Light and the Effect on Metabolic Syndrome and Alzheimer's Disease
This study's main hypothesis is that a delivering a tailored lighting intervention (TLI) will provide a successful means for promoting circadian entrainment and treating metabolic disease and inflammation in patients with mild…
- Trial name
- NCT03777722
- Testing
- Tailored Lighting Intervention
- Where
- 3 sites in United States
- Volunteers
- 61 people
- Sponsor
- Icahn School of Medicine at Mount Sinai